CA-MANSCAPED
Male grooming. In this day and age, these two words can - and should - mean trimming and tidying up all areas of a man’s body, including the nether regions. You may have thought about it, or even partaken in this all-important activity and reaped the results! But was it as enjoyable as it was effective? And, more importantly, were you equipped with the right tools for the job?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005418/en/
If you are not already familiar with the pioneer below-the-waist grooming and hygiene brand , let us formally introduce you to MANSCAPED™ . This California-based startup has single-handedly disrupted the men’s grooming industry and created a completely new category in the consumer packaged goods space.
Born in 2016, the booming direct-to-consumer (DTC) company designs and develops premium products for groin and body grooming , while upholding a steadfast mission to empower the modern man to unabashedly grab ahold of his situation “down there”. We are proud to report that since inception, the stigma-shattering brand has utterly taken off.
Today, MANSCAPED announces its latest and most extensive expansion yet into the European Union , which augments its reach to 1 billion people worldwide . This follows successful international launches earlier this year into Canada, Australia, New Zealand, and the United Kingdom. With the holidays on the horizon, the perfect present or self-care treat is now just a click away for every lady and gentleman in more than 30 countries worldwide .
“Entering into Europe in one fell swoop is no small feat, but we’re confident we have the infrastructure and high-powered passion to fuel this momentous launch,” said Stephanie Hinze, MANSCAPED’s Senior Director of International Operations. “Sharing the European Union’s values of inclusion and non-discrimination, we believe our trusted brand and superior products have sparked a new era of well-being for all and will continue to propel a movement throughout the region. We’re particularly excited to have laid the groundwork just in time for the holiday season in order to offer only the best tools and formulations to so many more men and women throughout the world.”
If that news doesn’t excite consumers enough, this milestone is coupled with a new product launch that our international fans have been waiting for. That’s right, our very first above-the-waist tool * is now available in over 30 countries! Combine this groundbreaking device with our best-selling below-the-waist trimmer and skincare products, and you have a set of essentials that is a must-have for the men on your list...
Introducing The Performance Package , our newest luxury grooming kit that includes:
The Lawn Mower™ 3.0 - The legendary electric trimmer for the groin and body is the cornerstone of a refined grooming routine. The precision engineered device boasts a 7,000 RPM motor with QuietStroke™ technology and replaceable ceramic blade with MANSCAPED’s SkinSafe™ technology that helps reduce the risk of nicks, cuts, and snags. The 600mA Li-Ion rechargeable battery and waterproof ergonomic design allows for a safe and easy trimming session.
*The Weed Whacker™ - Now Available Internationally - This revolutionary electric ear and nose hair trimmer is a technological masterpiece, redesigning the traditional nose hair taming tool by focusing on maximum performance and comfort, and offering a sleek, ultramodern design. The tool features SkinSafe technology, a 9,000 RPM motor and 360-degree rotary dual-blade system, and intelligently contoured design.
Crop Preserver™ - Ball deodorant is a thing, and it’s life-changing. The anti-chafing formula is infused with cooling aloe vera and controls any stench coming from an unwanted “swamp crotch”.
Crop Reviver™ - This innovative ball toner is the solution for maintaining hygiene and cleanliness on-the-go. The restorative spray relieves high-friction areas and post-shave irritation with just a spritz or two.
As a leading DTC brand, MANSCAPED offers a one-stop-shop online where customers can browse the full collection and purchase items a la cart or as part of a bundle - all with guaranteed free shipping. For our new consumers residing in Europe, please visit eu.manscaped.com to learn more and join the MANSCAPED Movement today!
About MANSCAPED™:
Founded in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple and effective male grooming routine. MANSCAPED offers direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, and the European Union. Retail placement includes Target and Best Buy locations throughout the U.S., with further retail availability coming soon. MANSCAPED.com is a one-stop shopping destination for men looking for a brand that is focused on the needs of what has, for too long, been a sensitive and often taboo subject. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom